@misc{10481/77603,
year = {2022},
month = {9},
url = {https://hdl.handle.net/10481/77603},
abstract = {Trypanosoma cruzi, the causative agent of Chagas disease (CD), is a genuine parasite with tremendous genetic
diversity and a complex life cycle. Scientists have studied this disease for more than 100 years, and CD drug
discovery has been a mainstay due to the absence of an effective treatment. Technical advances in several areas
have contributed to a better understanding of the complex biology and life cycle of this parasite, with the aim of
designing the ideal profile of both drug and therapeutic options to treat CD. Here, we present the T. cruzi Arequipa
strain (MHOM/Pe/2011/Arequipa) as an interesting model for CD drug discovery. We characterized acutephase
parasitaemia and chronic-phase tropism in BALB/c mice and determined the in vitro and in vivo benznidazole
susceptibility profile of the different morphological forms of this strain. The tropism of this strain makes it
an interesting model for the screening of new compounds with a potential anti-Chagas profile for the treatment of
this disease.},
organization = {Alfonso Martin Escudero Foundation		
Junta de Andalucia		
A-CTS-383-UGR18},
publisher = {Elsevier},
keywords = {Arequipa strain},
keywords = {Benznidazole},
keywords = {Chagas disease},
keywords = {Chemotherapy},
keywords = {Drug discovery},
keywords = {Trypanosoma cruzi},
title = {Biological characteristics of the Trypanosoma cruzi Arequipa strain make it a good model for Chagas disease drug discovery},
doi = {10.1016/j.actatropica.2022.106679},
author = {Martín Escolano, Rubén and Rosales Lombardo, María José and Marín Sánchez, Clotilde},
}